Pipeline

BRY102

An oral candidate for neurodegenerative disease on a 505(b)(1) path, in preclinical development.

  1. Preclinical
  2. IND-enabling
  3. Phase 1

The program

BRY102 targets endpoints related to oxidative stress in rare neurological disorders.

Status

Preclinical development

Other programs

BRY101

Phase 1b dose finding

NAD+ medical food. Phase 1b dose finding to support wound healing.

BRY103

IND-enabling

Metabolic Modulator. 505(b)(2) candidate in IND-enabling studies.

BRY104

Preclinical

Oral peptide. 505(b)(1) IND candidate in preclinical development.